4,553 Shares of Moderna, Inc. $MRNA Purchased by Choreo LLC

Key Points

• Choreo LLC initiated a position in Moderna, buying 4,553 shares worth approximately $866,000 during the third quarter.
• Institutional investors and hedge funds own 75.33% of Moderna’s stock. Analysts’ consensus rating is Hold, with an average price target of $107.10.
• Moderna’s CFO and president sold shares under pre-arranged trading plans; insiders sold a combined 197,251 shares worth about $33.9 million over the past three months.

Choreo LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,553 shares of the company's stock, valued at approximately $866,000.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Moderna during the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP bought a new position in Moderna in the second quarter valued at approximately $564,272,000. Wellington Management Group LLP boosted its holdings in shares of Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company's stock valued at $172,384,000 after buying an additional 103,977 shares during the period. First Trust Advisors LP boosted its holdings in shares of Moderna by 59.3% in the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company's stock valued at $121,549,000 after buying an additional 891,072 shares during the period. Finally, Merck & Co. Inc. acquired a new position in shares of Moderna in the second quarter valued at approximately $161,642,545. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Rothschild & Co Redburn lowered shares of Moderna from a "neutral" rating to a "sell" rating and raised their price objective for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. CLSA raised shares of Moderna to an "outperform" rating in a research note on Friday, August 28th. TD Cowen reiterated a "buy" rating on shares of Moderna in a report on Wednesday, October 21st. Royal Bank Of Canada reissued a "sector perform" rating and issued a $130.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Moderna in a report on Wednesday, September 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Moderna presently has an average rating of "Hold" and an average target price of $107.10.

Insider Buying and Selling at Moderna

In other Moderna news, CFO Jamey Mock sold 34,836 shares of the business's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company's stock, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares of the company's stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 197,251 shares of company stock worth $33,875,904. Insiders own 10.80% of the company's stock.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s personalized cancer vaccine intismeran, used with Keytruda, reduced the risk of death or melanoma recurrence by 42% in a late-stage trial. The results bolster the candidate’s potential, though success in additional cancers and eventual commercial impact are not assured. Article: Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
• Neutral Sentiment: Moderna is scheduled to report third-quarter results on Nov. 6. Analysts expect sales of about $888.8 million and a loss of $1.37 per share, making the report a near-term catalyst for investors. Article: Buy Moderna Stock Before Q3 Earnings? Here's What to Know
• Negative Sentiment: Recent coverage warns that the stock’s steep rally and premium valuation could leave it vulnerable if earnings or vaccine-development news disappoints. One article also flags an obstacle to the cancer vaccine’s success, though the supplied article summary does not specify what it is. Article: Buy Moderna Stock Before Q3 Earnings? Here's What to Know
• Neutral Sentiment: Prediction markets have begun trading on FDA approval timing for the melanoma vaccine, raising questions about potential information leakage and insider trading. This adds regulatory and market scrutiny but does not itself indicate an FDA decision. Article: What Is Moderna Answering As FDA Vaccine Betting Markets Grow?

Moderna Stock Up 3.4%

NASDAQ MRNA opened at $228.44 on Wednesday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $254.48. The firm's 50 day moving average is $185.79 and its 200-day moving average is $88.36.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.